¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug phototoxic response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • drug-resistant
    ¾à¹°ÀúÇ×-
  • designer drug
    º¯Á¶¾à¹°
  • fixed drug eruption
    °íÁ¤¾à¹°¹ßÁø, °íÁ¤¾àÁø
  • gateway drug
    Åë·Î¼ö´Ü¾à¹°, ½À°üÇü¼º¾à¹°
  • generic drug name
    ÀϹݾà¸í
  • hallucinogenic drug
    ȯ°¢Á¦
  • inotropic drug
    ¼öÃàÃËÁø¾à
  • mucosal protective drug
    Á¡¸·º¸È£Á¦
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • narcotic drug
    ¸¶¾à
  • new drug application
    ½Å¾àÇã°¡½Åû
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • orphan drug
    Èñ±Í¾à
  • prescription drug
    󹿾à
  • prokinetic drug
    À§Àå¿îµ¿ÃËÁøÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • drug treatment
    ¾à¹°Ä¡·á
  • drug withdrawal
    ¾à¹°±Ý´Ü
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • drug utilization review
    ¾à¹°»ç¿ë°ËÅä
  • drug-induced hemolysis
    ¾àÁ¦À¯¹ß¿ëÇ÷
  • drug-induced hepatitis
    ¾à¹°°£¿°
  • drug-induced jaundice
    ¾à¹°À¯¹ßȲ´Þ
  • drug-induced purpura
    ¾à¹°À¯¹ßÀÚ»ö¹Ý
  • drug-induced retinopathy
    ¾àÀ¯¹ß¸Á¸·º´Áõ
  • drug-induced rhinitis
    ¾à¹°À¯¹ßÄÚ¿°, ¾à¹°À¯¹ßºñ¿°
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
  • hallucinogenic drug
    (¢¡hallucinogen) ȯ°¢Á¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´(Ä¡·á)¾à.
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î(¼º)¾à.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦, Ç×¹«½ºÄ«¸°(¼º)¾à
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸¾à (ù÷ÝþØ»å·).
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ¾à.
  • antipruritic drug
    Ç×¼Ò¾ç¾à£¬Áø¾ç¾à(òååÊå·), °¡·Á¿òÁ¦Áö¾à.
  • antipsychotic drug
    Ç×Á¤½Åº´¾à(ù÷ïñãêÜ»å·).
  • antipsychotic drug
    Ç×Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­¾à(ú°æðå·).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
ANSWER Agency for Toxic Substances and Disease Registry/National Library of Medicine's Workstation for Emer...
ARS acquiescence response scale; adult Reye's syndrome; alcohol-related seizures; alizarin red S; Americ...
AS-SCORE age, stage of disease, physiological system involved, complications, response to therapy
BAER brainstem auditory evoked response
BERA brainstem evoked response audiometry
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
MDT Multi drug therapy
MDR Multi-drug resistant
MDR-TB Multi-drug resistant tuberculosis
MDR Multiple Drug Resistance
NHSDA National Household Survey of Drug Abuse
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • storage of drug
    ¾à¹°ÀÇ º¸°ü
  • sulfa drug
    ¼³ÆÄÁ¦
  • sustained action drug
    ÁöÈ¿¼º ¾àÁ¦
  • sustained release drug
    ÁöÈ¿¼º ¾àÁ¦
  • topical dental drug
    µµÆ÷¿ë Ä¡°ú ¾àÁ¦
  • tranquilizing drug
    Á¤¿ÂÁ¦, Á¤½Å ¾ÈÁ¤Á¦
    °¨Á¤ »óÅ¿¡ ÀÛ¿ëÇÏ´Â ¾à¹°·Î¼­, ȯÀÚÀÇ ÀǽÄÀ» ȥʽÃŰÁö ¾Ê°í Á¶¿ëÈ÷ ¶Ç´Â Æò¿ÂÇÏ°Ô ÇÏ´Â °Í. À̰ÍÀº ±Ù½É, °ÆÁ¤ »óÅÂ, ½Å°æÁõ ¹× Á¤½Å Àå¾Ö µîÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù.
  • untoward drug effect
    ¾à¹°ÀÇ ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Â È¿°ú
    ¿ì¸®°¡ ¿øÇÏ´Â Ä¡·á ¸ñÀû¿¡ ºÎÇÕÇÏ´Â ¾à¸® ÀÛ¿ëÀÌ ¾Æ´Ï¶ó ÀÎü¿¡ ÇØ°¡µÇ´Â µ¶ ÀÛ¿ë ¶Ç´Â ºÎÀÛ¿ë.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
drug interaction <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other.
(18 Jul 2002)
drug labelling Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
(12 Dec 1998)
drug monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
(12 Dec 1998)
drug, over-the-counter Drug for which a prescription is not needed.
(12 Dec 1998)
drug packaging Containers, packaging, and packaging materials for drugs and biological products. These include those in ampule, capsule, tablet, solution or other forms. Packaging includes immediate-containers, secondary-containers, and cartons. In the united states, such packaging is controlled under the federal food, drug, and cosmetic act which also stipulates requirements for tamper-resistance and child-resistance. Similar laws govern use elsewhere. drug labeling is also available.
(12 Dec 1998)
drug pathogenesis The production of morbid symptoms by drugs.
(05 Mar 2000)
drug, prescription A drug requiring a prescription, a physician's order. By comparison with an over-the-counter drug.
(12 Dec 1998)
drug psychosis Psychosis following or precipitated by ingestion of a drug, e.g., LSD.
(05 Mar 2000)
drug rash Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.
(12 Dec 1998)
drug residues Drugs and their metabolites which are found in the edible tissues and milk of animals after their medication with specific drugs. This term can also apply to drugs found in adipose tissue of humans after drug treatment.
(12 Dec 1998)
drug resistance The ability of bacteria and other microorganisms to withstand a drug to which they were once sensitive (and were once stalled or killed outright).
(12 Dec 1998)
drug resistance, microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through plasmids containing resistance factors (r factors).
(12 Dec 1998)
drug resistance, multiple Simultaneous resistance to a broad spectrum of structurally and functionally distinct drugs following exposure to a single agent. It is thought to result from the overexpression of genes encoding an integral plasma membrane protein, p-glycoprotein.
(12 Dec 1998)
drug resistance, neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
(12 Dec 1998)
drug resistant Unresponsive to the desired effects of drugs or other therapy for example: irradiation cytotoxic agents or hormones. Drug resistance of cells within tumours is probably the major cause of treatment failure.
(16 Dec 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á